T-cell activation against multiple patient-specific lymphoma antigens

This entry describes a therapeutic approach, not a molecule: T-cell activation against multiple patient-specific lymphoma antigens refers to strategies—most notably, CAR T-cell therapies—where T cells (often from the patient) are engineered or directed to recognize and attack lymphoma cells expressing a variety of antigens that are unique to or highly expressed in that patient's tumor. Unlike classical drug targets (such as a single receptor or enzyme), this process leverages both natural and synthetic immune recognition elements (TCR or CAR) to trigger cytotoxic T-cell responses, aiming to overcome immune evasion by lymphomas through multi-antigen targeting or personalized antigen selection. This field's clinical impact has been demonstrated in several hematological malignancies, particularly B-cell lymphomas, using CAR T cells with anti-CD19 and anti-CD22 specificity among others. Key safety challenges include life-threatening cytokine release syndrome and tumor escape if targeted antigens are lost or downregulated by the tumor.

Other names

patient-specific T-cell lymphoma antigen responselymphoma antigen-directed T-cell activationmulti-antigen-specific T-cell response in lymphoma

Not a single molecule, but general mechanisms involve: T-cell receptor/CAR binding to antigen on lymphoma cell → T-cell activation → cytotoxicity via perforin/granzyme or death receptor pathways; Enhanced cytokine secretion and immune synapse formation; Overcoming immunosuppression or immune evasion mechanisms by tumor cells, including antigen loss, T-cell exhaustion, and inhibitory signals (PD-1/PD-L1, LAG-3, TGF-β).